ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Akeso and InnoCare Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AkesoInnoCare Pharma
studies on the registry16667
open to participants now6739
phase 3 studies under way2514
reach primary completion within a year297
programswith a study of their own in two years1710

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAkesoInnoCare Pharma
Phase 1

Akeso: 6 of its 17 programs at phase 1

  1. AK 135phase 1
  2. AK150phase 1
  3. AK152phase 1
  4. AK154phase 1
  5. AK157D1 for injectionphase 1

and 1 more — sign in to see them all

35%

InnoCare Pharma: 3 of its 10 programs at phase 1

  1. ICP-538phase 1
  2. ICP-B161 (SC or IV)phase 1
  3. ICP-B794phase 1
30%
Phase 2

Akeso: 5 of its 17 programs at phase 2

  1. AK139phase 2
  2. AK138D1phase 2
  3. AK146D1phase 2
  4. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2
  5. tinengotinibphase 2
29%

InnoCare Pharma: 4 of its 10 programs at phase 2

  1. ICP-490phase 2
  2. ICP-322phase 2
  3. ICP-B208phase 2
  4. ICP-B381phase 2
40%
Phase 3

Akeso: 6 of its 17 programs at phase 3

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. ligufalimabphase 3
  4. AK120phase 3
  5. ebronucimabphase 3

and 1 more — sign in to see them all

35%

InnoCare Pharma: 3 of its 10 programs at phase 3

  1. mesutoclaxphase 3
  2. ICP-332phase 3
  3. ICP-488phase 3
30%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Akeso8 readouts · 1 phase 3

Akeso, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cadonilimabphase 3 · Nov 0 · NCT06341335

Akeso, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2 · Dec 0 · NCT06943820
  2. ivonescimabphase 3 · Dec 0 · NCT05689853
  3. AK139phase 2 · Dec 27 · NCT07436221
  4. ligufalimabphase 3 · Dec 30 · NCT05227664
····

Akeso, May ’27: 1 program whose next study reaches primary completion

  1. tinengotinibphase 2 · May 10 · NCT07052253

Akeso, Jun ’27: 1 program whose next study reaches primary completion

  1. AK152phase 1 · Jun 0 · NCT07301502
··

Akeso, Sep ’27: 1 program whose next study reaches primary completion

  1. AK146D1phase 2 · Sep 1 · NCT07591090
·
InnoCare Pharma5 readouts · 1 phase 3

InnoCare Pharma, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ICP-332phase 3 · Nov 25 · NCT06775860
···

InnoCare Pharma, Mar ’27: 2 programs whose next study reaches primary completion

  1. ICP-322phase 2 · Mar 0 · NCT07236099
  2. ICP-488phase 3 · Mar 0 · NCT07440537
··

InnoCare Pharma, Jun ’27: 1 program whose next study reaches primary completion

  1. mesutoclaxphase 3 · Jun 0 · NCT06656494
··

InnoCare Pharma, Sep ’27: 1 program whose next study reaches primary completion

  1. ICP-B381phase 2 · Sep 0 · NCT07901413
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Akeso

New programs 2

Reached a new phase 0

None

Study stopped 1

Primary completion later 1

InnoCare Pharma

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionAkesoInnoCare Pharma
Dermatitis, Atopicboth · compare here

Akeso in Dermatitis, Atopic: 2 programs

  1. AK120phase 3
  2. AK139phase 2

Their studies: Akeso’s studies of Dermatitis, Atopic in search

InnoCare Pharma in Dermatitis, Atopic: 1 program

  1. ICP-332phase 3

Their studies: InnoCare Pharma’s studies of Dermatitis, Atopic in search

Psoriasisboth · compare here

Akeso in Psoriasis: 1 program

  1. gumokimabphase 3

Their studies: Akeso’s studies of Psoriasis in search

InnoCare Pharma in Psoriasis: 2 programs

  1. ICP-332phase 3
  2. ICP-488phase 3

Their studies: InnoCare Pharma’s studies of Psoriasis in search

Chronic Urticariaboth · compare here

Akeso in Chronic Urticaria: 1 program

  1. AK139phase 2

Their studies: Akeso’s studies of Chronic Urticaria in search

InnoCare Pharma in Chronic Urticaria: 1 program

  1. ICP-332phase 3

Their studies: InnoCare Pharma’s studies of Chronic Urticaria in search

Leukemia, Myeloid, Acuteboth · compare here

Akeso in Leukemia, Myeloid, Acute: 1 program

  1. ligufalimabphase 3

Their studies: Akeso’s studies of Leukemia, Myeloid, Acute in search

InnoCare Pharma in Leukemia, Myeloid, Acute: 1 program

  1. mesutoclaxphase 3

Their studies: InnoCare Pharma’s studies of Leukemia, Myeloid, Acute in search

Prurigoboth · compare here

Akeso in Prurigo: 1 program

  1. AK139phase 2

Their studies: Akeso’s studies of Prurigo in search

InnoCare Pharma in Prurigo: 1 program

  1. ICP-322phase 2

Their studies: InnoCare Pharma’s studies of Prurigo in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Akeso 4 of 17 · InnoCare Pharma 0 of 10 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.